Universal Biosensors (ASX:UBI) shares were flat on Friday, even as the microcap healthcare company inked a US distribution deal for its blood monitoring sensors.
UBI’s Xprecia Prime device is a portable handheld device used to analyse patients with blood coagulation issues (thrombosis) when taking medicines like Warfarin and Coumadin.
The company has US regulatory approval for sale of its devices in the States and in a new deal with distributor Henry Schein – “one of the USA’s largest and most influential distributors of medical products” – it will now have a partner to that end for the next twelve months.
Notably, Henry Schein hasn’t got UBI caught up in exclusivity in this contract, leaving the door open to potential other relationships alongside – something UBI wants to see as it fleshes out its US operations.
Sales are expected to kick off before the start of 2025.
“Henry Schein undertook a comprehensive product review before agreeing to partner Xprecia Prime,” UBI CEO John Sharman said.
“Henry Schein service thousands of coagulation clinics and hospitals throughout the USA which can now access Xprecia Prime through the Henry Schein network.
“Over recent months we have recruited key staff to build our USA Xprecia business. We continue to negotiate additional distribution deals for Xprecia in the USA and we look forward to reporting our progress.”
UBI last traded at 12.5cps.
Join the discussion: See what HotCopper users are saying about Universal Biosensors and be part of the conversations that move the markets.
